Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Dec;138(6):882-7.

Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study

Mukul Kumar, Ashu Rastogi, Sanjay Kumar Bhadada  1 , Anil Bhansali, Kim Vaiphei, Rakesh Kochhar
Affiliations
Randomized Controlled Trial

Effect of zoledronic acid on bone mineral density in patients of celiac disease: a prospective, randomized, pilot study

Mukul Kumar et al. Indian J Med Res. 2013 Dec.

Abstract

Background & objectives: The symptoms of celiac disease (CD) are varied and metabolic bone disease (MBD) is less recognized amongst all manifestations in CD patients. Bone disease in CD is attributed to secondary hyperparathyroidism, which in turn is associated with increased bone remodelling. Improvement in bone mineral density (BMD) with gluten free diet (GFD) is known, but the data on efficacy of bisphosphonates in CD patients are limited. Bisphosphonates being a potent inhibitor of bone resorption may be useful in patients with CD having low BMD. The aim of the present investigation was to study the effect of zoledronic acid on BMD in CD patients.

Methods: A total of 28 CD patients were randomized to receive GFD, calcium and cholecalciferol (group A), and zoledronic acid (group B). Baseline biochemical tests and T-score by dual energy x-ray absorptiometer were done and repeated after 12 months.

Results: The T-score showed improvement in the control arm (group A) from -3.31 ± 1.46 to -2.12 ± 1.44, a gain of 35.9 per cent (P<0.05) and in drug arm (group B) -2.82 ± 1.27 to -1.06 ± 1.84, registering a gain of 62.4 per cent (P<0.001). However, there was no difference in improvement of T-score in zoledronic acid group as compared to the control group.

Interpretation & conclusions: Administration of zoledronic acid was not found to be better than GFD alone in increasing BMD in CD patients with low BMD in this pilot study.

PubMed Disclaimer

Figures

Fig
Fig
Flow chart of randomization of study subjects.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Green PHR, Christophe C. Celiac disease. N Engl J Med. 2007;57:1731–43. - PubMed
    1. Bhadada SK, Bhansali A, Kochhar R, Menon AS, Sinha SK, Dutta P, et al. Does every short stature child need screening for celiac disease? J Gastroenterol Hepatol. 2008;23:353–6. - PubMed
    1. Bhadada SK, Bhansali A, Ravikumar P, Kochhar R, Nain CK, Dutta P, et al. Changing scenario in aetiological profile of short stature in India-growing importance of celiac disease: a study from tertiary care centre. Indian J Pediatr. 2011;78:41–4. - PubMed
    1. Bhadada SK, Kochhar R, Bhansali A, Dutta U, Kumar PR, Poornachandra KS, et al. Prevalence and clinical profile of celiac disease in type 1 diabetes mellitus in north India. J Gastroenterol Hepatol. 2011;26:378–81. - PubMed
    1. Katz S, Weinerman S. Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol. 2010;6:506–17. - PMC - PubMed

Publication types